Published in Cancer Immunol Immunother on March 25, 2009
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol (2010) 2.12
Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res (2013) 1.63
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck (2010) 1.45
Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol (2010) 1.37
Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin Cancer Res (2011) 1.34
Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest (2014) 1.29
Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res (2011) 1.26
The emerging role of nimotuzumab in the treatment of non-small cell lung cancer. Biologics (2010) 1.26
Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs (2010) 1.25
New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res (2010) 1.17
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy. Front Immunol (2015) 1.11
CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. Cancer Res (2015) 1.11
Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol (2015) 1.10
Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin Cancer Res (2009) 1.09
Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors. J Oncol (2009) 1.03
Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancer. Oral Oncol (2011) 0.97
Radioimmunotherapy of solid tumors: searching for the right target. Curr Drug Deliv (2011) 0.96
Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines. Surgery (2012) 0.95
Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma. Hum Immunol (2010) 0.94
TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells. Cancer Immunol Immunother (2013) 0.93
TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells. Oncoimmunology (2013) 0.92
STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients. Cancer Immunol Res (2015) 0.92
The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. Biologics (2010) 0.91
Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan. Br J Clin Pharmacol (2012) 0.90
Preclinical modeling of EGFR inhibitor resistance in head and neck cancer. Cancer Biol Ther (2012) 0.90
Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression. Neoplasia (2012) 0.90
Bi-specific aptamers mediating tumor cell lysis. J Biol Chem (2011) 0.87
Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. PLoS One (2013) 0.87
Cancer immunotherapy: Progress and challenges in the clinical setting. Eur J Immunol (2011) 0.86
Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resist Updat (2011) 0.86
High plasma fibrinogen is correlated with poor response to trastuzumab treatment in HER2 positive breast cancer. Medicine (Baltimore) (2015) 0.85
NK cell-based immunotherapies in Pediatric Oncology. J Pediatr Hematol Oncol (2015) 0.85
Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer. Contemp Oncol (Pozn) (2013) 0.85
High efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors. J Transl Med (2013) 0.85
Immune biomarkers of anti-EGFR monoclonal antibody therapy. Ann Oncol (2014) 0.84
Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. Cancer (2013) 0.83
CD137 stimulation enhances cetuximab induced natural killer (NK): dendritic cell (DC) priming of anti-tumor T cell immunity in head and neck cancer patients. Clin Cancer Res (2016) 0.82
Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity. PLoS One (2016) 0.81
Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity. Semin Oncol (2014) 0.80
Cetuximab-dependent ADCC in cancer: dream or reality? Cancer Immunol Immunother (2010) 0.80
Cetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids. Front Immunol (2015) 0.80
Molecular characterization of head and neck cancer: how close to personalized targeted therapy? Mol Diagn Ther (2012) 0.78
Dynamic contrast-enhanced computed tomography to assess early activity of cetuximab in squamous cell carcinoma of the head and neck. Radiol Oncol (2015) 0.78
Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial. BMC Cancer (2016) 0.78
c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity. Cancer Immunol Res (2014) 0.78
EGFR-targeted mAb therapy modulates autophagy in head and neck squamous cell carcinoma through NLRX1-TUFM protein complex. Oncogene (2016) 0.76
Role of trastuzumab in the management of HER2-positive metastatic breast cancer. Breast Cancer (Dove Med Press) (2010) 0.76
Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients. Clin Cancer Res (2016) 0.75
Expression of the chemokine CXCL14 and cetuximab-dependent tumour suppression in head and neck squamous cell carcinoma. Oncogenesis (2016) 0.75
Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms. J Immunol (2017) 0.75
The role of Fc-FcγR interactions in the anti-tumor activity of therapeutic antibodies. Immunol Cell Biol (2016) 0.75
Pharmacokinetics and Biodistribution Study of 7A7 Anti-Mouse Epidermal Growth Factor Receptor Monoclonal Antibody and Its F(ab')(2) Fragment in an Immunocompetent Mouse Model. ISRN Pharmacol (2012) 0.75
Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients. Front Pharmacol (2017) 0.75
Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy. Front Pharmacol (2017) 0.75
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood (2002) 8.76
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol (2008) 6.90
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol (2003) 6.77
Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res (2002) 4.97
Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol (2006) 3.67
Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res (1993) 3.62
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res (2006) 3.28
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol (2007) 2.83
Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck (2007) 2.49
Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res (2004) 2.41
Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res (2007) 2.31
Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res (2007) 2.20
Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res (2007) 2.14
Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res (2007) 1.88
Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol (2001) 1.87
Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res (2004) 1.85
The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res (2007) 1.66
Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. Anticancer Res (2007) 1.51
Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg (2007) 1.45
Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev (2007) 1.38
Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Mol Cancer Ther (2006) 1.18
FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. Haematologica (2007) 1.15
Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer (2007) 1.12
Correlates and determinants of nuclear epidermal growth factor receptor content in an oropharyngeal cancer tissue microarray. Cancer Epidemiol Biomarkers Prev (2008) 1.09
Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin Cancer Res (2008) 1.06
Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck patients. Laryngoscope (2005) 1.02
Abrogation of head and neck squamous cell carcinoma growth by epidermal growth factor receptor ligand fused to pseudomonas exotoxin transforming growth factor alpha-PE38. Clin Cancer Res (2004) 0.88
Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII. Radiother Oncol (2007) 0.88
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Head and neck cancer. Lancet (2008) 6.33
Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol (2006) 3.67
Technology for automated, rapid, and quantitative PCR or reverse transcription-PCR clinical testing. Clin Chem (2005) 3.42
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res (2009) 3.30
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res (2006) 3.28
Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab (2011) 2.93
Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol (2007) 2.57
Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck (2007) 2.49
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res (2011) 2.31
First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov (2012) 2.31
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov (2013) 2.29
Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res (2005) 2.28
Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis. J Natl Cancer Inst (2006) 2.21
Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med (2010) 2.21
Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur J Cancer (2006) 2.16
Outcomes of sublobar resection versus lobectomy for stage I non-small cell lung cancer: a 13-year analysis. Ann Thorac Surg (2006) 2.12
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol (2010) 2.12
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol (2009) 2.12
Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12
For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top. Clin Cancer Res (2012) 2.09
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest (2009) 2.08
STAT-mediated EGFR signaling in cancer. J Cell Biochem (2007) 2.05
Radiofrequency ablation of pulmonary malignant tumors in nonsurgical candidates. J Thorac Cardiovasc Surg (2003) 2.04
Lost in Translation: Obstacles to Translational Medicine. J Transl Med (2004) 2.03
TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression. Cancer Res (2012) 1.98
Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol (2007) 1.95
STAT3 signaling: anticancer strategies and challenges. Mol Interv (2011) 1.95
Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res (2012) 1.89
SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res (2004) 1.88
Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J Biol Chem (2003) 1.88
Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res (2004) 1.85
The mutational landscape of adenoid cystic carcinoma. Nat Genet (2013) 1.83
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) (2010) 1.80
In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene (2005) 1.78
HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res (2008) 1.77
Chemokine C receptor 7 expression and protection of circulating CD8+ T lymphocytes from apoptosis. Clin Cancer Res (2005) 1.73
STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ (2002) 1.69
Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy. Ann Thorac Surg (2009) 1.68
Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol (2004) 1.68
Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res (2005) 1.68
Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol (2003) 1.67
HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res (2006) 1.65
Monoclonal antibodies for cancer immunotherapy. Lancet (2009) 1.64
Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res (2013) 1.63
Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res (2008) 1.63
The impact of health insurance status on the survival of patients with head and neck cancer. Cancer (2010) 1.58
HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res (2009) 1.57
American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer. Thyroid (2012) 1.57
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer Prev Res (Phila) (2013) 1.56
Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene (2005) 1.56
Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia (2004) 1.56
Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol (2003) 1.55
Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells. Clin Cancer Res (2011) 1.54
Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci (2008) 1.50
Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol (2006) 1.49
Comprehensive genome and transcriptome analysis of the 11q13 amplicon in human oral cancer and synteny to the 7F5 amplicon in murine oral carcinoma. Genes Chromosomes Cancer (2006) 1.49
Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget (2014) 1.49
Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res (2006) 1.48
Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma. J Invest Dermatol (2005) 1.48
Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother (2007) 1.47
Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res (2006) 1.45
Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg (2007) 1.45
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck (2010) 1.45
High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer (2013) 1.43
Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity. Cancer Res (2006) 1.43
Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys (2006) 1.42
Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas. JAMA (2007) 1.41
Comparison of surgical techniques for early-stage thymoma: feasibility of minimally invasive thymectomy and comparison with open resection. J Thorac Cardiovasc Surg (2011) 1.41
Polyclonality of BRAF mutations in acquired melanocytic nevi. J Natl Cancer Inst (2009) 1.40
Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial. J Clin Oncol (2010) 1.40
Bile exposure inhibits expression of squamous differentiation genes in human esophageal epithelial cells. Ann Surg (2012) 1.40
Alteration of microRNA profiles in squamous cell carcinoma of the head and neck cell lines by human papillomavirus. Head Neck (2011) 1.40
HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol (2002) 1.39
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res (2004) 1.39
Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev (2007) 1.38
Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol (2010) 1.37